Literature DB >> 9756372

Tumour necrosis factor-alpha as a target of melanocortins in haemorrhagic shock, in the anaesthetized rat.

D Altavilla1, M M Cainazzo, F Squadrito, S Guarini, A Bertolini, C Bazzani.   

Abstract

The cytokine tumour necrosis factor-alpha (TNF-alpha) is involved (mostly through the activation of inducible nitric oxide synthase) in the pathogenesis of circulatory shock. On the other hand, melanocortin peptides are potent and effective in reversing haemorrhagic shock, both in animals (rat, dog) and in humans. This prompted us to study the influence of the melanocortin peptide ACTH-(1-24) on the blood levels of TNF-alpha in haemorrhage-shocked rats and on the in vitro production of TNF-alpha by lipopolysaccharide (LPS)-activated macrophages. Plasma levels of TNF-alpha were undetectable before starting bleeding and greatly increased 20 min after bleeding termination in saline-treated rats. In rats treated with ACTH-(1-24) the almost complete restoration of cardiovascular function was associated with markedly reduced levels of TNF-alpha 20 min after bleeding termination. On the other hand, ACTH-(1-24) did not influence TNF-alpha plasma levels in sham-operated, unbled rats. In vitro, ACTH-(1-24) (25-100 nM) dose-dependently reduced the LPS-stimulated production of TNF-alpha by peritoneal macrophages harvested from untreated, unbled rats. These results indicate that inhibition of TNF-alpha overproduction may be an important component of the mechanism of action of melanocortins in reversing haemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756372      PMCID: PMC1565580          DOI: 10.1038/sj.bjp.0702038

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage.

Authors:  D Giuliani; C Mioni; C Bazzani; D Zaffe; A R Botticelli; S Capolongo; A Sabba; M Galantucci; A Iannone; P Grieco; E Novellino; G Colombo; A Tomasi; A Catania; S Guarini
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

3.  Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.

Authors:  Francesca Vaglini; Carla Pardini; Teresa Di Desidero; Paola Orlandi; Francesco Pasqualetti; Alessandra Ottani; Simone Pacini; Daniela Giuliani; Salvatore Guarini; Guido Bocci
Journal:  Mol Neurobiol       Date:  2017-08-08       Impact factor: 5.590

4.  Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock.

Authors:  F Squadrito; S Guarini; D Altavilla; G Squadrito; G M Campo; M Arlotta; C Quartarone; A Saitta; D Cucinotta; C Bazzani; M M Cainazzo; C Mioni; A Bertolini; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Hydrogen Gas Inhalation Attenuates Endothelial Glycocalyx Damage and Stabilizes Hemodynamics in a Rat Hemorrhagic Shock Model.

Authors:  Tomoyoshi Tamura; Motoaki Sano; Tadashi Matsuoka; Joe Yoshizawa; Ryo Yamamoto; Yoshinori Katsumata; Jin Endo; Koichiro Homma; Mayumi Kajimura; Masaru Suzuki; Eiji Kobayashi; Junichi Sasaki
Journal:  Shock       Date:  2020-09       Impact factor: 3.533

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.